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Background: Rifaximin is a minimally absorbed antibiotic with high luminal activity, used to treat various
gastrointestinal diseases. Although rifaximin has been proposed as first line treatment for small intestinal bacterial
overgrowth (SIBO), few data are available regarding its efficacy in non-IBS subjects. We aimed to assess the ability
of rifaximin to normalize lactulose-H2 breath tests in non-IBS subjects with symptoms suggestive of SIBO.
Materials and methods: Consecutive non-IBS patients presenting with bloating and flatulence were prospectively
recruited and submitted to lactulose-H2 breath testing (LBT). Patients who had a positive result were offered rifaximin
1200 mg daily for 10 days. Breath testing was repeated two weeks after treatment completion in all patients in order to
assess for response.
Results: A total of 19 patients with a positive result received rifaximin and repeated the breath test (7 (36.8%) males,
age 56.5 ± 17.6 years). The mean peak hydrogen excretion was 13.7 ± 2.8 and 10.3 ± 7.3 ppm at baseline and following
rifaximin treatment, respectively (t = 1.98, p = 0.06). LBT normalized in 8/19 (42.1%) subjects. No patients reported
symptom resolution. No adverse events were reported.
Discussion: Strengths include the study's prospective design. Limitations include the small sample size and
open label design.
Conclusion: Rifaximin was not effective in normalizing LBT in our cohort of non-IBS subjects with symptoms
suggestive of SIBO.Introduction and background
Small intestinal bacterial overgrowth (SIBO) is a hetero-
geneous disorder with a clinical presentation ranging
from florid malabsorption to minor, non-specific or an
absence of symptoms [1]. SIBO is commonly defined as
the presence of at least 1 × 105 colony forming units of
bacteria per milliliter in a duodenal aspirate [2]. Al-
though classically associated with motility disorders and
anatomical abnormalities of the upper gastrointestinal
tract, SIBO may be more prevalent than previously
thought. This increased prevalence may be due to the
availability of noninvasive, inexpensive and easily applic-
able alternative diagnostic test to direct assay of a duo-
denal aspirate, such as the lactulose-hydrogen breath test
(LBT) [3]. Furthermore, LBT testing allows for serial* Correspondence: dboltin@gmail.com
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unless otherwise stated.testing and provides an objective measure of treatment re-
sponse. Indeed, normalization of the LBT correlates with
symptom improvement in IBS patients [4]. Antibiotics are
the mainstay of treatment for SIBO. Minimally-absorbed
antibiotics, such as rifaximin, offer a theoretical advantage
by allowing maximal luminal activity with few systemic
adverse effects. Nevertheless, the efficacy of such treat-
ment, as measured by LBT negativity, varies greatly in the
reported literature, ranging from 2% to 91% [5,6].
Several studies have assessed rifaximin in patients with
SIBO and IBS [7-10]. A recent meta-analysis found that
4-64% of IBS subjects may have a positive diagnostic test
suggestive of SIBO. There is controversy whether such
IBS patients should be diagnosed as IBS, or rather con-
sidered as SIBO, since the symptoms of IBS and SIBO
overlap [11]. Given the ambiguity surrounding the etio-
logical role of SIBO in IBS patients, and given the fact
that rifaximin may be beneficial for the treatment of IBS
even in the absence of SIBO [12], it follows that in order
to assess the efficacy of rifaximin for the treatment oftd. This is an Open Access article distributed under the terms of the Creative
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should be used. This is the first study to assess the effi-
cacy of rifaximin in a non-IBS cohort. The rationale for
treating SIBO in non-IBS subjects stems from the sig-
nificant correlation observed between clinical symptoms
related to SIBO and abnormal diagnostic tests [13].
Aim
The aim of this study is to assess the efficacy of rifaxi-




Between January 2012 and July 2013 consecutive patients
over 18 years-old, presenting to the neurogastroenterology
clinic at our institution with primary symptoms of bloat-
ing and flatulence, were prospectively recruited, and sub-
jected to LBT. None of the subjects complained of chronic
recurrent abdominal pain or fulfilled the Rome III criteria
for irritable bowel syndrome [14].
Patients who used antibiotics during the previous
6 months, currently used laxatives or promotility agents,
or had received bowel preparation for colonoscopy or
capsule endoscopy within 30 days, were excluded. Add-
itional exclusion criteria were presence of pancreatic
exocrine insufficiency or major concomitant diseases
(including active malignancy, hepatic failure and renal in-
sufficiency), hypersensitivity to antibiotics belonging to
the rifamycin and/or tetracyclin families, patient unwill-
ingness or inability to provide informed consent, and pa-
tient inability to fully complete all phases of the study.
Finally, we excluded pregnant and lactating women, as
well as premenopausal women not using contraception.
The study was conducted in accordance with the prin-
ciples of the Declaration of Helsinki and Good Clinical
Practice (GCP) and was approved by the Human Subjects
Protection Program of Rabin Medical Center.
Clinical assessment
Prior to LBT, all patients were assessed at a dedicated
neurogastroenterology clinic by a study physician (RD)
for a thorough clinical assessment and to confirm the
absence of IBS. Following LBT patients returned to the
study physician for rifaximin prescription and continued
to be monitored on an individualized basis. Symptoms
were monitored at clinic visits which were scheduled
fortnightly.
Rome III diagnostic questionnaire for irritable
bowel syndrome
This self-assessed standardized and validated questionnaire
was developed by the Rome Foundation Board to identify
functional gastrointestinal disease. For the diagnosis of IBS,patients must have recurrent abdominal pain or discomfort
for at least 3 months in the previous 6 months, with
2 or more of the following symptoms: (1) relief with
defecation, (2) onset associated with a change in fre-
quency of stool, and (3) onset associated with a change in
form (appearance) of stool. All screened subjects com-
pleted a validated Hebrew language Rome III Diagnostic
Questionnaire for IBS [14]. Only patients that did not ful-
fill the Rome III criteria for IBS were included and were
offered treatment with rifaximin.
SIBO Evaluation
LBT was performed according to standard protocols [15].
Each subject was submitted to LBT (EC 60 Gastrolyzer 2,
Bedfont Scientific, Rochester, UK) following a 3 day low
carbohydrate diet, overnight fasting, and chlorhexidine
mouthwash. Samples of end-expiratory air were collected
before oral administration of 15 g lactulose diluted in
400 mL of water, every 15 min for 90 minutes (15, 30, 45,
60, 75, 90 minutes). The accuracy of the Gastrolyzer
was ±2% of reading. The sensor sensitivity was 1 ppm. The
test was considered positive for SIBO when an increase
over the baseline level was >10 ppm, on the basis of estab-
lished validation data [16,17].
SIBO Eradication
Non-IBS patients with a positive LBT received treatment
with rifaximin 1200 mg daily for 10 days (Normix, Alfa
Wassermann, Italy). Patients were reassessed with LBT
two weeks after completion of treatment.
Statistical analysis
All analyses were performed using SPSS version 21.0
statistical analysis software (IBM Inc, Chicago, IL, USA).
Distributions of continuous variables were assessed for
normality using the Kolmogorov-Smirnov test (cutoff at
p < 0.1). Distributions of all continuous variables devi-
ated significantly from normal so were described as me-
dian (min-max) in addition to mean ± standard deviation.
Continuous variables were compared by rifaximin treat-
ment exposure using the student's t-test. Nominal variables
were described as frequency counts and presented as n(%).
Nominal variables were compared using the chi square
test. We calculated that at least 22 patients needed to be
recruited in order to have a 90% chance of detecting a 50%
rate of breath test normalization following treatment with
rifaximin. All tests were two-sided and considered signifi-
cant at p < 0.05.
Results
Demographics
A total of 53 non-IBS patients underwent LBT of whom
22 patients (41.5%) had a positive LBT result. All patients
were offered primary treatment with rifaximin (1200 mg
Table 1 Characteristics of patients receiving rifaximin for




Age, years (SD) 56.5 (17.6)
Medications
Anticholinergics 5 (26.3)
Calcium channel blocker 3 (15.8)
Proton pump inhibitor 12 (63.2)
Comorbidities
Diabetes mellitus 5 (26.3)
Sjogren’s syndrome 1 (12.5)
Penicillin allergy 3 (15.8)
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not undergo follow-up LBT, and therefore 19 patients
(7 (36.8%) males, aged 56.5 ± 17.6 years) were included
in the final set analysis (Figure 1).
Clinical characteristics
The clinical characteristics of patients receiving rifaximin
for SIBO are shown in Table 1. Among the 19 non-IBS pa-
tients receiving rifaximin for treatment of LBT-diagnosed
SIBO, 13 (68.4%) received antisecretory therapy, 5 (26.3%)
reported diabetes mellitus and 2 patients reported collagen
vascular disease.
SIBO Eradication
The mean peak hydrogen excretion was 13.68 ± 2.83 and
10.26 ± 7.30 ppm at baseline and following rifaximin
treatment, respectively (t = 1.98, p = 0.06). Following
treatment with rifaximin, LBT normalized in 8/19 (42.1%)
subjects, and LBT recordings decreased in 12/19 (63.2%)
subjects. In 7/19 (36.8%) subjects the LBT recording in-
creased or remained unchanged (Figure 2). No difference
in demographic or clinical characteristics was observed be-
tween rifaximin responders and non-responders (Table 2).
No patients reported any degree of resolution of either
bloating or flatulence. No adverse events were reported.
Discussion
In the present study we describe a prospective cohort of
subjects receiving the non-absorbable antibiotic rifaximin
for LBT-diagnosed SIBO. Treatment success, measured byFigure 1 Study Flowchart.normalization of LBT, was only 42%. This is the first such
study to emanate from our geographical region.
The dosage of rifaximin 1200 mg and the treatment
duration of 10 days was chosen in accordance with pre-
vious data demonstrating its superior efficacy compared
to lower doses [18,19]. Rifaximin has a broad spectrum
of activity, especially against anaerobic intestinal bacteria,
including Bacteroides, Lactobacilli and Clostridia, which
are frequently responsible for the metabolic derangements
in SIBO patients. Its activity profile resembles rifamycin,
however toxicity is low since it is minimally absorbed from
the gut [20].
Previous studies have assessed the efficacy of rifaximin
in IBS patients with symptoms compatible with SIBO.
Up to 84% of patients with IBS have a positive LBT, sug-
gesting that the etiology and symptom manifestation of
IBS and SIBO may overlap [4]. Pimental, et al. in the
landmark TARGET trial, randomized IBS patients with-
out constipation to receive rifaximin 1650 mg or placebo
for two weeks. Adequate relief of IBS symptoms was re-
ported in 40.8% and 31.2% of treatment and placebo
groups, respectively (p = 0.01). However, in their study no
breath test was performed at baseline or following treat-
ment [21]. Meyrat, et al. treated LBT-positive IBS patients
with rifaximin, and demonstrated that treatment was asso-
ciated with significant improvement in symptoms. LBT
negativity was 86% following rifaximin treatment, more
than twofold the rate we observed in our non-IBS cohort
[7]. Several other nonrandomized open labeled studies
have reported similar results [8-10]. A recently published
meta-analysis concluded that rifaximin is, indeed, more
efficacious than placebo for global IBS symptom improve-
ment [OR = 1.57, 95% CI: 1.22–2.01, therapeutic gain 9.8%,
number needed to treat (NNT) = 10.2] [12].
We can speculate that the efficacy of rifaximin in IBS
may be unrelated to SIBO, since IBS patients with a
Figure 2 Peak Hydrogen Excretion at Baseline and Following Rifaxamin.
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improvement. This concurs with our experience in non-
IBS SIBO patients in whom symptom improvement was
absent or minimal, and suggests that rifaximin is effect-
ive treatment for symptoms of IBS, but not for the
normalization of LBT in patients with bloating and flatu-
lence. Nevertheless, the presence of IBS cannot account
for the marked discrepancy in LBT normalization rates







N (%) 8 (42.1) 11 (57.9) 0.74
Male 2 (25) 5 (75) 0.37
Age, years (SD) 57.6 (19.5) 55.6 (17.1) 0.72
Medications
Anticholinergics 1 (12.5) 4 (36.4) 0.31
Calcium channel blocker 1 (12.5) 2 (18.2) 1.00
Proton pump inhibitor 5 (62.5) 7 (63.6) 1.00
Comorbidities
Diabetes mellitus 3 (37.5) 2 (18.2) 0.61
Scleroderma 0 (0) 0 (0) 1.00
Sjogren’s syndrome 1 (12.5) 1 (9.1) 1.00most likely explanation is related to geographical, dietary
or ethnic differences in microbiome [22].
In addition to IBS, the rate of LBT normalization fol-
lowing rifaximin therapy has been reported in pediatric
patients (20-64%) [23,24], patients with ileal Crohn’s dis-
ease (100%) [25], microscopic colitis (71%) [26], celiac
disease (4%) [27], chronic acid suppression (87%) [6],
diabetes (86%) [28], diverticulitis (100%) [29] and systemic
sclerosis (73%) [30]. Despite the fact that treatment proto-
cols vary widely between studies, and irrespective of clin-
ical endpoints, the efficacy of rifaximin for the treatment
of SIBO assessed by LBT is clearly unpredictable. This fact
is corroborated by our study. No studies to date have spe-
cifically targeted patients with SIBO in the absence of IBS
or any of the aforementioned associated comorbid condi-
tions for rifaximin therapy.
Several studies have examined a potential role for pre-
and probiotics in combination with rifaximin for the
treatment of suspected SIBO. Normalization of LBT is
significantly higher in patients who receive rifaximin in
combination with prebiotics, compared to rifaximin
alone (87.1% vs. 62.1%, p = 0.02) [31]. Sequential treat-
ment of SIBO with rifaximin and probiotics appears more
efficacious than rifaximin and prebiotics with respect to
symptom reduction [32]. In fact, some centers recommend
sequential treatment with rifaximin followed by probiotics
as a standard approach to treating SIBO [8].
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its small size, and open label design. Our power analysis
indicated that 22 subjects needed to be recruited, how-
ever this was based on the assumption that at least 50%
of subjects treated with rifaximin would have a normal
LBT at follow-up. In retrospect, 50% was a slight over-
estimation, as normalization was actually achieved in
42.1% subjects. We did not include a thorough clinical
evaluation or screening period, and therefore no conclu-
sions can be drawn regarding the effect of rifaximin on
symptoms. Nevertheless, as a laboratory-based study,
our results are valid insofar as they demonstrate that
rifaximin does not consistently normalize LBT in SIBO
patients. A further limitation of our study is related to
the ongoing controversy regarding the validity and inter-
pretation of LBT in SIBO. Some clinicians do not regard
LBT as the de facto gold standard for the diagnosis of
SIBO, and demand indirect supportive evidence includ-
ing serum vitamin B12 levels and folate levels [16,33].
Inherent problems with LBT include difficulty in distin-
guishing SIBO from rapid intestinal transit where similar
gas production patterns are observed (false positivity)
[3]. In fact, it has been suggested that LBT positivity in
IBS patients may be related to rapid intestinal transit,
and not SIBO [34]. Finally, compliance was not assessed
with pill counts or used packages. Nevertheless, due to
the high cost of rifaximin treatment in Israel, we pre-
sume that compliance was high.
In conclusion, although most subjects with SIBO who
were exposed to rifaximin experienced a reduction in
peak hydrogen excretion, this reduction lacked statistical
significance. Rifaximin eradicated SIBO in fewer than
half of treated patients. Larger studies in non-IBS popu-
lations are necessary to verify our findings. Further re-
search should consider both clinical and laboratory
endpoints, and explore a potential role for pre- and pro-
biotics in the treatment of SIBO.Competing interests
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